Author

S. Beaver

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:imaging· 1 Assay:multiome· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Casper· 3 shared P. Battisti· 3 shared S. Reed· 3 shared A. Gerhardt· 2 shared D. Hanson· 2 shared E. A. Voigt· 2 shared J. Bakken· 2 shared J. Singh· 2 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

C. Casper

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Intranasal self-amplifying RNA SARS-CoV-2 vaccine produces protective respiratory and systemic immunity and prevents viral transmission

M. F. Jennewein, M. D. Schultz, S. Beaver, P. Battisti, J. Bakken, D. Hanson, J. Akther, F. Zhou, R. Mohamath, J. Singh, N. Cross, D. N. Kasal, M. Ykema, S. Reed, D. Kalange, , E. A. Voigt

This study compares intranasal and intramuscular delivery of a self-amplifying RNA SARS-CoV-2 vaccine, showing that intranasal delivery induces mucosal immunity and reduces viral transmission.

bioRxiv · Nov 10, 2022 · PreprintImmunology

A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability

E. A. Voigt, A. Gerhardt, D. Hanson, P. Battisti, S. Reed, J. Singh, R. Mohamath, M. F. Jennewein, J. Bakken, S. Beaver, C. Press, P. Soon-Shiong, C. J. Paddon, C. B. Fox, C. Casper

This paper develops a self-amplifying RNA vaccine against SARS-CoV-2 with room-temperature stability and strong immune responses in preclinical studies.

bioRxiv · Mar 22, 2022Immunology

Heteologous saRNA-Prime, DNA Dual-Antigen-Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies

A. Rice, M. Verma, E. Voigt, P. Battisti, S. Beaver, S. Reed, K. Dinkins, S. Mody, L. Zakin, S. Tanaka, B. Morimoto, W. Higashide, C. A. Olson, E. R. Gabitzsch, J. T. Safrit, , P. Soon-Shiong

This study evaluates heterologous vaccination with two SARS-CoV-2 vaccines in mice, finding enhanced humoral and T-cell responses and broad neutralizing activity against variants.

bioRxiv · Nov 29, 2021 · PreprintImmunology